

**FORM 51-102F3**

**MATERIAL CHANGE REPORT**

**Item 1. Name and Address of Company**

**OVATION SCIENCE INC.**  
Suite 1140 – 625 Howe Street  
Vancouver, BC, V6C 2T6

**Item 2. Date of Material Change**

September 14, 2022

**Item 3. News Release**

The news release was issued on September 14, 2022 and filed on [www.sedar.com](http://www.sedar.com).

**Item 4. Summary of Material Change**

Ovation Science Inc. announced that it has received Patent Protection until 2041 for transdermal creams formulated with CBD and THC.

**Item 5. Full Description of Material Change**

Ovation Science Inc. ("Ovation" or the "Company") announced that it the U.S. Patent and Trademark Office (USPTO) has granted Ovation a patent entitled "Composition and Method for Transdermal Delivery of Cannabidiol (CBD) and 9-Tetrahydrocannabinol (THC)"; (US Patent Number: 11,439,602), with an expiry of February 2041.

This patent is a significant achievement for the Company's R&D department which uses pharmaceutical drug development methods to optimize the transdermal delivery of topical cannabis products. The patent covers the Company's innovative transdermal creams formulated with a combination of CBD and THC and delivered by its proprietary drug delivery system Invisicare®. It protects both the composition as well as a method for formulating a transdermal delivery composition based on a desired ratio of CBD to THC through skin tissue. Ovation has also filed for similar patent protection in Canada.

**Item 6. Reliance on Subsection 7.1(2) or (3) of National Instrument 51-102**

Not applicable.

**Item 7. Omitted Information**

None.

**Item 8. Executive Officer**

**Terry Howlett**  
CEO  
604-685-4745

**Item 9. Date of Report**

September 14, 2022